High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3991-4006

  Mukthavaram, Rajesh ^a   Jiang, Pengfei ^a   Saklecha, Rohit ^a   Simberg, Dmitri ^a,c   Bharati, Ila Sri ^a   Nomura, Natsuko ^a   Chao, Ying ^a   Pastorino, Sandra ^a   Pingle, Sandeep C ^a   Fogal, Valentina ^a   Wrasidlo, Wolf ^a,b   Makale, Milan ^a,b   Kesari, Santosh ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Biodistribution; Efficacy; Glioblastoma; Liposomes; Staurosporine

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; STAUROSPORINE;

ANALYTICAL PARAMETERS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER THERAPY; CELL DEATH; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG TO LIPID RATIO; ENCAPSULATION; ENZYME PHOSPHORYLATION; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL ENCAPSULATION; MALE; MOUSE; NONHUMAN; PH; PROTEIN CLEAVAGE; TUMOR CELL;

BIODISTRIBUTION; EFFICACY; GLIOBLASTOMA; LIPOSOMES; STAUROSPORINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DIFFUSION; FEMALE; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE C; STAUROSPORINE; TREATMENT OUTCOME;

EID: 84886083356     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51949     Document Type: Article

References (56)

1. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun. 1986;135(2): 397-402.
2. Zhang XD, Gillespie SK, Hersey P. Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther. 2004;3(2):187-197.
3. Schwartz GK, Redwood SM, Ohnuma T, Holland JF, Droller MJ, Liu BC. Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine. J Natl Cancer Inst. 1990;82(22):1753-1756.
4. Tang D, Lahti JM, Kidd VJ. Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem. 2000;275(13): 9303-9307.
5. Baltuch GH, Dooley NP, Couldwell WT, Yong VW. Staurosporine differentially inhibits glioma versus non-glioma cell lines. J Neurooncol. 1993;16(2):141-147.
6. Fuse E, Tanii H, Kurata N, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 1998;58(15):3248-3253.
7. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 1991;51(18):4888-4892.
8. Gurley LR, Umbarger KO, Kim JM, Bradbury EM, Lehnert BE. Staurosporine Analysis and its Pharmacokinetics in the Blood of Rats. Los Alamos, NM: Los Alamos National Laboratory; 1994.
9. Gescher A. Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol. 1998;31(5):721-728.
10. Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs. 1999;17(3):227-240.
11. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001;98(20):10983-10985.
12. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501.
13. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene. 2002;21(11):1727-1738.
14. Baldwin RM, Parolin DA, Lorimer IA. Regulation of glioblastoma cell invasion by PKC iota and RhoB. Oncogene. 2008;27(25):3587-3595.
15. Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol. 1997;4(10):796-801.
16. Friedman B, Fujiki H, Rosner MR. Regulation of the epidermal growth factor receptor by growth-modulating agents: effects of staurosporine, a protein kinase inhibitor. Cancer Res. 1990;50(3):533-538.
17. da Rocha AB, Mans DR, Regner A, Schwartsmann G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist. 2002;7(1):17-33.
18. Fischer U, Jänicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ. 2003;10(1): 76-100.
19. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6(2):99-104.
20. Affar EB, Germain M, Winstall E, et al. Caspase-3-mediated processing of poly(ADP-ribose) glycohydrolase during apoptosis. J Biol Chem. 2001;276(4):2935-2942.
21. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691-743.
22. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
23. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4): 987-992.
24. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res. 2001;7(2):223-225.
25. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198.
26. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2(2):83-90.
27. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58(7): 1408-1416.
28. Tschaikowsky K. Protein kinase C inhibitors suppress LPS-induced TNF production in alveolar macrophages and in whole blood: the role of encapsulation into liposomes. Biochim Biophys Acta. 1994;1222(1): 113-121.
29. Yamauchi M, Kusano H, Nakakura M, Kato Y. Reducing the impact of binding of UCN-01 to human alpha1-acid glycoprotein by encapsulation in liposomes. Biol Pharm Bull. 2005;28(7):1259-1264.
30. Yost SE, Pastorino S, Rozenzhak S, et al. High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. PLoS One. 2013;8(2):e56185.
31. Murphy EA, Majeti BK, Mukthavaram R, Acevedo LM, Barnes LA, Cheresh DA. Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther. 2011;10(6):972-982.
32. Hewavitharana AK, Shaw PN, Ng YK, Fuerst JA. Simple screening method for staurosporine in bacterial cultures using liquid chromatography-tandem mass spectrometry. J Bioanal Biomed. 2009;1(1):001-004.
33. Gurley LR, Umbarger KO, Kim JM, Bradbury EM, Lehnert BE. Development of a high-performance liquid chromatographic method for the analysis of staurosporine. J Chromatogr B Biomed Appl. 1995;670(1):125-138.
34. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta. 2004;1663(1-2):167-177.
35. Kurata N, Kuramitsu T, Tanii H, et al. Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01, in human plasma or urine. J Chromatogr B Biomed Sci Appl. 1998;708(1-2):223-227.
36. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8):3472-3481.
37. Rajesh M, Sen J, Srujan M, Mukherjee K, Sreedhar B, Chaudhuri A. Dramatic influence of the orientation of linker between hydrophilic and hydrophobic lipid moiety in liposomal gene delivery. J Am Chem Soc. 2007;129(37):11408-11420.
38. Page B, Page M, Noel C. A new fluorometric assay for cytotoxicity measurements in-vitro. Int J Oncol. 1993;3(3):473-476.
39. Jensen MM, Jørgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008;8:16.
40. Gurley LR, Umbarger KO, Kim JM, Bradbury EM, Lehnert BE. High-performance liquid chromatographic analysis of staurosporine in vivo. Its translocation and pharmacokinetics in rats. J Chromatogr B Biomed Sci Appl. 1998;712(1-2):211-224.
41. Fuse E, Tanii H, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res. 1999;59(5):1054-1060.
42. Hoffman WP, Ness DK, van Lier RB. Analysis of rodent growth data in toxicology studies. Toxicol Sci. 2002;66(2):313-319.
43. Clarke SJ, Farrugia DC, Aherne GW, Pritchard DM, Benstead J, Jackman AL. Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity. Clin Cancer Res. 2000;6(1):285-296.
44. Iwamoto H, Torimura T, Nakamura T, et al. Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia. 2011;13(3):187-197.
45. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49-60.
46. Anderson M, Omri A. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Deliv. 2004;11(1):33-39.
47. Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3 K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17(3):590-603.
48. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98(20):11598-11603.
49. Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A. 2008;105(27):9343-9348.
50. Tschaikowsky K, Brain JD. Staurosporine encapsulated into pH-sensitive liposomes reduces tnf production and increases survival in rat endotoxin shock. Shock. 1994;1(6):401-407.
51. Munson JM, Fried L, Rowson SA, et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med. 2012;4(127):127-136.
52. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66(6): 3271-3277.
53. Stensrud G, Sande SA, Kristensen S, Smistad G. Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int J Pharm. 2000;198(2):213-228.
54. Niu G, Cogburn B, Hughes J. Preparation and characterization of doxorubicin liposomes. Methods Mol Biol. 2010;624:211-219.
55. Sadzuka Y, Takabe H, Sonobe T. Liposomalization of SN-38 as active metabolite of CPT-11. J Control Release. 2005;108(2-3):453-459.
56. Fernandes AS, Gonçalves AP, Castro A, et al. Modulation of fungal sensitivity to staurosporine by targeting proteins identified by transcriptional profiling. Fungal Genet Biol. 2011;48(12):1130-1138.